- Home
- ADV vs CGEM Comparison
ADV vs CGEM Comparison
Compare ADV & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADV
- CGEM
- Stock Information
- Founded
- ADV 1987
- CGEM 2016
- Country
- ADV United States
- CGEM United States
- Employees
- ADV N/A
- CGEM N/A
- Industry
- ADV Business Services
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- ADV Consumer Discretionary
- CGEM Health Care
- Exchange
- ADV Nasdaq
- CGEM Nasdaq
- Market Cap
- ADV 417.2M
- CGEM 437.2M
- IPO Year
- ADV N/A
- CGEM 2021
- Fundamental
- Price
- ADV $1.17
- CGEM $8.63
- Analyst Decision
- ADV Strong Buy
- CGEM Strong Buy
- Analyst Count
- ADV 1
- CGEM 7
- Target Price
- ADV $2.50
- CGEM $26.00
- AVG Volume (30 Days)
- ADV 526.8K
- CGEM 848.8K
- Earning Date
- ADV 11-06-2025
- CGEM 11-06-2025
- Dividend Yield
- ADV N/A
- CGEM N/A
- EPS Growth
- ADV N/A
- CGEM N/A
- EPS
- ADV N/A
- CGEM N/A
- Revenue
- ADV $3,502,796,000.00
- CGEM N/A
- Revenue This Year
- ADV N/A
- CGEM N/A
- Revenue Next Year
- ADV $0.67
- CGEM N/A
- P/E Ratio
- ADV N/A
- CGEM N/A
- Revenue Growth
- ADV N/A
- CGEM N/A
- 52 Week Low
- ADV $1.04
- CGEM $5.68
- 52 Week High
- ADV $3.76
- CGEM $16.20
- Technical
- Relative Strength Index (RSI)
- ADV 35.12
- CGEM 59.63
- Support Level
- ADV $1.12
- CGEM $7.25
- Resistance Level
- ADV $1.39
- CGEM $8.49
- Average True Range (ATR)
- ADV 0.10
- CGEM 0.69
- MACD
- ADV 0.00
- CGEM 0.03
- Stochastic Oscillator
- ADV 10.00
- CGEM 86.48
About ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.